The whole-exome sequencing and whole-transcriptome sequencing-based test is approved for molecular profiling of solid tumors.

MRK posts better-than-expected third-quarter results. The company lowers its guidance, likely due to the soft sales ...

In oncology drugs, Keytruda sales are likely to have been ... Alliance revenues from Lenvima may have also boosted oncology sales. Sales of Welireg are likely to have been driven by the launch ...

With these approvals, KEYTRUDA is now authorized for 30 indications in the EU, including five in gynecologic cancers, Merck said in a statement. RAHWAY: Merck, also known as MSD outside the US and ...

RAHWAY, N.J. - Merck, known as MSD outside the United States and Canada, has received approval from the European Commission (EC) for two new indications of its anti-PD-1 therapy, KEYTRUDA® ...

Merck’s (NYSE:MRK) blockbuster cancer therapy Keytruda (pembrolizumab) has been cleared by the European Commission to treat two new indications in gynecologic cancers. The first approval is for ...